BMP4 up-regulation of FGFR2IIIb and other TEC-specific factors. (A) Northern blot analysis in 427 cell lines (upper panel) and Taqman real-time RT-PCR analysis of dexoyguanosine-treated FTOC (lower panel) for FGFR2IIIb expression with BMP4 treatment. Increase in FGFR2IIIb levels in 427 cell line is approximately 1.63-fold with BMP4 treatment. Increase with Taqman analysis is significant (^*) with greater than 99.9% confidence. (B) Northern blot analysis of 427 cells (upper panel) and RT-PCR analysis of deoxyguanosine-treated FTOC (lower panel) for Foxn1 expression with BMP4 treatment. Increase in Foxn1 levels in 427 cell lines is approximately 1.7-fold with BMP4 treatment; quantitation was performed with Quantity One analysis software. (C) Semiquantitative RT-PCR analysis of deoxyguanosine-treated FTOC with BMP4 alone or BMP4 plus FGFR2IIIb/Fc inhibitor for FGFR2IIIb, ELC, and eotaxin with hypoxanthine phosphoribosyltransferase (HPRT) and actin as controls. Note: FGFR2IIIb/Fc inhibits BMP4-stimulated ELC and eotaxin expression (lanes 8 versus 9, 11 versus 12). Changes in ELC (lanes 10-12) and eotaxin (lanes 7-9) are quantified as shown. Quantification was performed by means of ImageQuant software analysis. Error bars indicate mean ± SD.